Mosunetuzumab Plus Polatuzumab Vedotin Shows Improved Outcomes vs Rituximab Plus Polatuzumab Vedotin Among Patients With R/R Large B-Cell Lymphoma
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates and no excessive toxicities versus rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), according to phase 2 study results.
These results were presented by Adam Olszewski, MD, Legorreta Cancer Center at Brown University, Providence, Rhode Island, and colleagues at the 66th ASH Annual Meeting in San Diego, California.
“These results strongly support the continued evaluation of the M (SC)-Pola regimen being investigated in the [phase 3] SUNMO study,” the study authors added.
Source:
Chavez JC, Olszewski A, Bastos-Oreiro M, et al. A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). Dec 7-10, 2024; San Diego, CA. Abstract: 989
